For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in ...

Women taking a new breast cancer drug are living longer than those taking Tamoxifen - the current 'gold standard' treatment. Doctors predict the new drug, Arimidex, will improve long-term survival ...

Switching to an AI following 2–3 years of initial adjuvant tamoxifen is an effective option for patients unable to begin treatment with an AI. This article evaluates the most up-to-date results ...

Dr Nidhan Biswas, the lead investigator from NIBMG, emphasised how this study moves India closer to personalised cancer care.